Klochkov Sergey G, Neganova Margarita E, Nikolenko Vladimir N, Chen Kuo, Somasundaram Siva G, Kirkland Cecil E, Aliev Gjumrakch
Institute of Physiologically Active Compounds, Russian Academy of Sciences, Chernogolovka, 142432, Russia.
Sechenov First Moscow State Medical University (Sechenov University), 8-2 Trubetskaya St., Moscow, 119991, Russia.
Semin Cancer Biol. 2021 Feb;69:190-199. doi: 10.1016/j.semcancer.2019.08.028. Epub 2019 Aug 22.
The use of nanoparticles dramatically increases the safety and efficacy of the most common anticancer drugs. The main advantages of nano-drugs and delivery systems based on nano-technology are effective targeting, delayed release, increased half-life, and less systemic toxicity. The use of nano-carriers has led to significant improvements in drug delivery to targets compared with traditional administration of these drugs. In this review, the main tendencies in nano-drug formulations as well as factors limiting their use in clinical settings are discussed. Additionally, the current status of approved nano-drugs for cancer treatment is reviewed.
纳米颗粒的使用显著提高了最常见抗癌药物的安全性和有效性。基于纳米技术的纳米药物和递送系统的主要优点是有效靶向、缓释、半衰期延长和全身毒性降低。与这些药物的传统给药方式相比,纳米载体的使用已使药物向靶点的递送有了显著改善。在本综述中,讨论了纳米药物制剂的主要趋势以及限制其在临床环境中使用的因素。此外,还综述了已批准用于癌症治疗的纳米药物的现状。